The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Patients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 ((223)Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ming-Hao, Dai, Jin-Dong, Zhang, Xing-Ming, Zhao, Jin-Ge, Sun, Guang-Xi, Zeng, Yu-Hao, Zeng, Hong, Xu, Nan-Wei, Zeng, Hao, Shen, Peng-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411251/
https://www.ncbi.nlm.nih.gov/pubmed/36695246
http://dx.doi.org/10.4103/aja2022108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411251/
https://www.ncbi.nlm.nih.gov/pubmed/36695246
http://dx.doi.org/10.4103/aja2022108

Ejemplares similares